Autolus Therapeutics Ltd (AUTL NASDAQ) stock market data APIs
$1.8804
0.08(4.3%)
as of September 11, 2026
Try our APIs with
free plan!
Autolus Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Prev. Close
1.8804
Open
1.9615
High
1.9998
Low
1.8628
52 wk Range
1.175-2.58
Market Cap
500 M
Shares Outstanding
266 M
Revenue
1 079 K
EPS
-0.15
Beta
1.995
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Autolus Therapeutics Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Autolus Therapeutics Ltd data using free add-ons & libraries
Get Autolus Therapeutics Ltd Fundamental Data
Autolus Therapeutics Ltd Fundamental data includes:
- Net Revenue: 1 079 K
- EBITDA: -68 942 608
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Autolus Therapeutics Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Autolus Therapeutics Ltd News
New
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product revenue hit $45.7 million, ...
Autolus (AUTL) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Executive Director of Investor Relations - Amanda Cray Chief Executive Officer - Dr. Christian Itin Chi...
Autolus Q2 Net Loss Narrows As AUCATZYL Sales Surge 119%; CARLYSLE Data Expected By Year-End
(RTTNews) - Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, announced financial results for the second quarter reflecting approximately 119% revenue growth from AUCATZYL...
Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
Woman in mask and gown holding a test tube ©Adobe Stock Images Autolus Therapeutics plc (NASDAQ:AUTL) shares rose 3.19% in pre-market trading on Tuesday after the biotechnology company delivered bet...
Get Autolus Therapeutics Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
